Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignancy linked to asbestos exposure. On a genomic level, MPM is characterized by frequent chromosomal deletions of tumor suppressors, including microRNAs. MiR-137 plays a tumor suppressor role in other cancers, so the aim of this study was to characterize it and its target Y-box binding protein 1 (YBX1) in MPM.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive malignancy arising from the mesothelial lining of the pleural cavity after asbestos exposure. Present therapeutic options for MPM are limited-the current standard combination of cisplatin and pemetrexed is largely palliative and provides a modest median survival of 12.1 months. 1, 2 Despite resounding epidemiological evidence associating asbestos consumption and MPM incidence, nine of the 10 most populous countries in the world have yet to implement a complete asbestos ban. 3, 4 Factoring in the extended latency period between asbestos exposure and MPM development (30-50 years), global MPM incidence is expected to rise within the next decade. 3 Therefore, better characterization of MPM biology to aid in the development of new therapeutic strategies is essential.
Next-generation sequencing data has confirmed an association between MPM development and the loss of three key tumor suppressors. 5 Downregulation of p16 (encoded by cyclin-dependent kinase inhibitor 2A gene [CDKN2A] ) is linked to copy number loss of region 9p21-22.
6 p16 acts on cyclin-dependent kinases such as cyclindependent kinase 4, and homozygous deletion of CDKN2A has been reported in 65% to 70% of MPM samples. 6, 7 The deubiquitinating hydrolase BRCA1 associated protein 1 (BAP1) functions in DNA damage response and cell cycle regulation, 8 and the BRCA1 associated protein 1 gene (BAP1 gene) located on chromosome 3p21.1 is deleted in 40% of MPM cases. 9 Finally, merlin, a cytoskeletal protein encoded by neurofibromin 2 gene (NF2) at 22q12.2, mediates contact inhibition in normal cells and is an upstream suppressor of the Hippo pathway. 10 It is deleted in more than 40% MPM cases, with dysregulation of the Hippo pathway occurring in 80%. 11 In addition to these regions, deletion of 1p21-22 has been reported in up to 70% of MPM cases, 9, 12 but to our knowledge there is little information regarding the implications of 1p21-22 deletion for MPM biology. Interestingly, the deletion of this region was significantly associated with 9p21-22 locus loss in MPM, 13 which (in addition to CDKN2A) is also home to the microRNA (miRNA) miR-31, a tumor suppressor that is also frequently lost through homozygous deletion of this region.
14 miRNAs are small, noncoding RNAs that are fundamentally involved in the regulation of almost all biological processes. 15 Many are located at fragile sites and are often silenced in cancer through deletion or promoter hypermethylation. 15, 16 The dysregulation of numerous miRNAs has been linked to the development and progression of human cancer, and recently, miRNA-based therapeutics have shown promise in tumors such as MPM. 17, 18 As the consequences of 1p21-22 locus deletion in MPM biology are poorly understood, we investigated the role of miR-137 in MPM because its host gene is located at 1p21. 3 . MiR-137 has demonstrated tumorsuppressive activity in colorectal cancer (CRC) and glioblastoma multiforme, 19, 20 although its role in MPM is unknown. Here, we characterize the expression and functions of miR-137 in MPM and explore the role of one of its targets, Y-box binding protein-1 (YBX1), in the context of MPM biology.
Materials and Methods

Cell Culture
Cells were maintained in Roswell Park Memorial Institute medium supplemented with 10% heatinactivated fetal bovine serum (both Thermo Fisher Scientific, Waltham, MA) in a humidified atmosphere (5% CO 2 at 37 C Transfection with MicroRNA Inhibitors, Mimics, and siRNAs miRCURY miR-137 locked nucleic acid (LNA) inhibitor and miRCURY LNA inhibitor negative controls were purchased from Exiqon (Vedbaek, Denmark) (Supplementary Table 2 ). MiR-137 mimic, Y-box binding protein 1 gene (YBX1)-specific small interfering RNA (siRNA), and validated negative control mimic and siRNA were purchased from Shanghai GenePharma (Shanghai, China) (see Supplementary Table 2 ). Cells were reverse-transfected using 0.1% Lipofectamine RNAiMAX (Thermo Fisher Scientific) as per the manufacturer's protocol.
Copy Number Variation
Genomic DNA was extracted using the QIAamp DNA mini kit (Qiagen, Hilden, Germany). Primer sequences and a schematic representation of their location are in Supplementary Table 3 and Supplementary Fig. 1 . Copy number variation (CNV) of the miR-137 host gene (MIR137HG) region was assessed by droplet digital polymerase chain reaction (PCR) using Evagreen (Bio-Rad, Hercules, CA). Ribonuclease P/MRP subunit 30 gene (RPP30) was used as a reference gene and HindIII was used to digest DNA (New England Biolabs, Ipswich, MA). Droplets were generated with a QX200 droplet generator and read on a QX200 droplet reader (both Bio-Rad) per the manufacturer's guidelines.
MSP and Genomic DNA Extraction
Methylated-and unmethylated-specific primers (Supplementary Table 4 ) were designed within CpG islands surrounding the MIR137HG gene by using the MethPrimer methylation mapping program, 23 as per standard methylation-specific polymerase chain reaction (MSP) design guidelines. Genomic DNA was extracted. Buffy coat DNA and EpiTech Control unmethylated DNA (Qiagen) served as methylation negative controls. HCT116 DNA served as a methylation positive control, as MIR137HG is methylated in this cell line. 19 Bisulphite conversion was conducted with an EZ DNA methylation kit (Zymo Research, Irvine, CA). End point PCR (AmpliTaq GOLD DNA kit, Thermo Fisher Scientific) and quantitative MSP (qMSP) using HCT116 as a methylation calibrator was conducted with the aforementioned primers and the KAPA SYBR FAST kit (KAPA Biosystems, Wilmington, MA) per the manufacturer's guidelines (see Supplementary Table 4 ). Methylation-specific primers for a region of the actin beta gene (ACTB) which no CpG sites were found were used as a reference gene for qMSP (see Supplementary Table 4 ). End point PCR products were run on an agarose gel and visualized on a Kodak Gel Logic 2200 imaging system (Eastman Kodak Company, Rochester, NY).
Assessing pri-miR-137 Expression in Mouse MPM Xenograft Models
Xenografts were grown by injecting H226 and MSTO cells subcutaneously into BALB/c nude mice. The mice were killed and the tumors were surgically removed. Samples were snap-frozen and homogenized, and RNA was isolated by using TRIzol. The use of animals was approved by the Sydney South West Area Health Service (2011-007). The primers and probes for human or mouse pri-miR-137 are in Supplementary Table 5 .
Luciferase Reporter Assay
A fragment of YBX1 3 0 untranslated region containing the miR-137 binding site was cloned from cDNA from SPC212 cells and amplified using AmpliTaq Gold 360 (Promega, Madison, WI) with specific primers (Supplementary Table 6 ). PCR amplicons were cloned into the TOPO TA vector (Thermo Fisher Scientific) and subcloned into the pSiCheck2 plasmid (Promega). The sequence was confirmed by Sanger sequencing at the Ramaciotti Centre (University of New South Wales, Sydney, Australia). The reporter construct (1 mg), with miRNA mimic or controls (5 nM) were transfected in 2 Â 10 5 cells in six-well plates. A dual luciferase assay (Promega) was performed per the manufacturer's protocol 48 hours after transfection.
Protein Isolation and Western Blot
Cells were transfected with 5 nM miRNA mimic, siRNAs, or controls. After indicated time points, protein was isolated in radioimmunoprecipitation assay buffer (including protease inhibitor cocktail [Roche Diagnostics, Mannheim, Germany]) and the concentration was measured by using a Pierce bicinchoninic protein assay (Thermo Fisher Scientific). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and blotted onto polyvinylidene fluoride membranes. Immunodetection was performed using a monoclonal rabbit anti-YBX1 antibody (Abcam, Cambridge, UK; 1:1000). b-actin (Sigma Aldrich, Dorset, UK) served as a loading control. Densitometry was performed with ImageJ. 24 
Videomicroscopy
Cells (2 Â 10 3 ) were seeded into eight-well chamber slides (Ibidi, Planegg, Germany). Forty-eight hours after transfection with 5 nM of either miR-137 mimic, YBX1 siRNA, or controls, cells were treated with 2 mg/mL mitomycin-C for 2 hours. The next day, cells were stained with cell tracker (Abcam) for 30 minutes. Videos were generated using a PALM MicroBeam laser microdissection microscope (Zeiss, Oberkochen, Germany) with pictures taken every 30 minutes for 25 hours. The distance migrated by at least 40 single cells was manually tracked with ImageJ software.
Agarose-Spot Invasion Assay
Cells (1.2 Â 10 5 ) were transfected with 5 nM miR-137 mimic, YBX1 siRNA, or the respective controls. The next day, cells were treated with 2 mg/mL mitomycin-C for 2 hours and then replated into 24-well plates prepared with agarose spots consisting of 7.5 mL 2% lowmelting agar containing 0.4% fetal bovine serum (adapted from Cheng et al. 2014 25 ). Images were taken after 48 hours and quantified with ImageJ software. 
Results
Copy Number Variation and Promoter Hypermethylation Contribute to Aberrant miR-137 Expression in MPM
Basal miR-137 expression was determined in a panel of 11 MPM cell lines and the immortalized mesothelial cell line MeT-5A by RT-qPCR. MiR-137 was aberrantly expressed in most cell lines compared with MeT-5A. Four cell lines (H2052, H28, H226, and VMC23) expressed notably lower and one (VMC40) expressed notably higher miR-137 levels (Fig. 1A) . To better understand this variable expression, we determined the copy number status of the exon encoding MIR137HG by digital droplet PCR. CNV was evident in seven of 11 cell lines (Fig. 1B) . Although there was no significant correlation, two low-expressing cell lines (H2052 and VMC23) also exhibited loss of heterozygosity (LOH), and VMC40 and MSTO, which had among the highest levels of miR-137, displayed copy number gains.
We suspected that methylation of the MIR137HG promoter also contributes to the variable expression observed, so we investigated the effects of the demethylating agent 5-aza-cytidine (5-Aza) on miR-137 expression. 5-Aza upregulated miR-137 in all cell lines, particularly in the low-expressing subgroup, which demonstrated marked miR-137 reexpression (Fig. 1C) . To confirm that the response to 5-Aza was due to methylation of the MIR137HG promoter, we conducted qMSP. The four low-expressing cell lines exhibited high miR-137 promoter methylation, whereas high-expressing cell lines exhibited low promoter methylation; the exception was MSTO, which also displays gene amplification (Fig. 1D) . We then conducted end point MSP to confirm our qMSP data in the highest-(VMC40) and lowest-(VMC23) expressing cell lines (Fig. 1E) .
To validate our CNV data, we performed gene expression arrays and array comparative genomic hybridization to assess MIR137HG expression and copy number status in a larger, partially overlapping set of cell lines (n ¼ 22). In that panel, a similar variable expression pattern was seen ( Supplementary  Fig. 2 ), and there was significant correlation between miR-137 expression and MIR137HG copy number status (Spearman's r ¼ 0.58442, p ¼ 0.00429) (Fig. 1F) .
To see whether the variable miR-137 expression was also evident in MPM tumor samples, we determined the expression of miR-137 in 115 MPM tumor and 23 normal mesothelial FFPE tissue specimens. Consistent with our results in cell lines, both MPM tumor and normal mesothelial tissue exhibit highly variable miR-137 expression ( Fig. 2A) . To assess the potential contribution of stromal cells to miR-137 levels, we measured human and mouse pri-miR-137 expression in mouse xenografts. We found that hsapri-miR-137 expression was overwhelmingly higher than mmu-pri-miR-137 expression, suggesting that the observed miR-137 primarily originates from tumor cells and stromal contribution is limited (Fig. 2B) . The effect of high and low miR-137 levels (defined by more than a twofold change to the median of the tumor cohort) on patient survival was analyzed by utilizing a Kaplan-Meier curve (Fig. 2C) . Patients with low miR-137 expression survived significantly longer than patients with high miR-137 expression (p ¼ 0.0065, Mantle-Cox test). To validate these findings and to analyze CNV and methylation in patient samples, we determined the expression of miR-137 in a smaller cohort of F/F samples (n ¼ 12). We found a similar spread of expression (Fig. 2D) and, when analyzed with the same parameters as the FFPE cohort, patients with low miR-137 expression also survived significantly Tables 7 and 8 . CNV of the MIR137HG was determined by using the same protocol as in Figure 1B , and although one sample demonstrated LOH and two copy number gains, this did not correlate with expression (Fig. 2F) . We conducted qMSP using the same protocol as in Figure 1D . Of the six samples displaying relatively low miR-137 expression, three displayed higher levels of methylation, which was consistent with our cell line data (Fig. 2G) .
miR-137 Suppresses MPM Cell Growth and Colony Formation
As we showed that high miR-137 expression is associated with poor patient outcome, we investigated the effect on growth of inhibiting its expression with a miR-137 miRCURY LNA inhibitor in eight MPM cell lines. Inhibitor transfection resulted in a decrease of miR-137 expression ( Supplementary Fig. 3 ), but no significant effect on growth was observed in any cell line over 96 hours (Fig. 3A) . As a subgroup of MPM cells lines and patient samples displayed reduced expression of miR-137, we also investigated the effect of increasing miR-137 levels using a miRNA mimic. Mimic transfection led to increased miR-137 levels (see Supplementary  Fig. 3 ) as well as significant growth inhibition over 96 hours in seven of eight cell lines (Fig. 3B) . Generally, cell lines expressing low or moderate endogenous miR-137 (MM05, Ren, H2452, SPC212) displayed greater growth inhibition in response to miR-137 mimic, compared with the higher-expressing cell lines (VMC40, VMC20). MiR-137 mimic transfection also disrupted colony formation in five of eight MPM cell lines (Fig. 3C) .
miR-137 Regulates Cell Migration and Invasion
The effect of miR-137 on cell migration was assessed by live cell videomicroscopy and manual single-cell tracking. MiR-137 mimic transfection significantly reduced the motility of low (H28, VMC23) or moderate (SPC212) miR-137-expressing cells compared with mimic control transfection. VMC40, which expresses high miR-137 levels, was unaffected ( Fig. 4A and B) . Wound healing assays performed on the same cell lines after transfection with miR-137 or control mimic confirmed these observations (Fig. 4C) . Invasion was investigated by using agarose-spot assays after mimic transfection, which significantly reduced the invasive potential of all MPM cells. Again, these effects were more prominent in cell lines expressing low-to-moderate levels of miR-137 (SPC212, H28, and VMC23) (Fig. 4D) .
miR-137 Targets the Oncoprotein YBX1, Which Is Highly Expressed in MPM
After transfecting six MPM cell lines with miR-137 mimic and miR-137 LNA inhibitor, we quantified the expression of several cancer-associated miR-137 target genes. AKT/serine threonine kinase 2 gene (AKT2), cyclin-dependent kinase 6 gene (CDK6), and YBX1 transcripts were unaffected by miR-137 LNA inhibitor transfection but were significantly down-regulated in response to miR-137 mimics (Fig. 5A) . We then focused on the miR-137/YBX1 interaction, as it was the most prominently down-regulated target. MiR-137 also downregulated YBX1 protein in three of four cell lines; VMC40 (with high miR-137) showed no change in YBX1 levels, although it has low basal YBX1 expression (Fig. 5B) . The 3 0 untranslated region of YBX1 linked to a luciferase reporter demonstrated that miR-137 directly binds to YBX1 (Fig. 5C) .
Basal YBX1 protein and YBX1 mRNA levels were analyzed by Western blot and RT-qPCR in all MPM cell lines and the mesothelial cell line MeT-5A and were found to be significantly correlated (Pearson's r ¼ 0.6584, p ¼ 0.0276, Supplementary Fig. 4 ). YBX1 protein expression showed a significant inverse correlation with basal miR-137 expression (Spearman's r ¼ -0.64693, p ¼ 0.03145) (Fig. 5D) . Importantly, irrespective of basal miR-137 expression, YBX1 levels were consistently higher in MPM cell lines than in the MeT-5A cell line (see Fig. 5D [red line]), implying an important role of YBX1 in MPM biology.
YBX1 Knockdown Decreases MPM Cell Proliferation, Colony Formation, Migration, and Invasion
To determine whether downregulation of YBX1 contributes to the tumor-suppressing activity of miR-137, we performed several assays after transfection with YBX1-specific siRNA alone and in combination with miR-137 mimic. RNA interference-mediated YBX1 knockdown significantly decreased YBX1 mRNA and YBX1 protein levels ( Supplementary Fig. 5 ). Proliferation assays showed that VMC40 (with low YBX1 levels) was only moderately affected, whereas VMC23 and SPC212 (high YBX1 levels) showed a significant decrease in cell growth by YBX1 reduction by siRNA alone and in combination with mimic (Fig. 6A) . H28 cells were unaffected by YBX1 knockdown alone but showed significantly reduced growth in combination with miR-137, indicating that targets other than YBX1 are important to growth in this cell line. We also conducted colony formation, invasion, and motility assays. Importantly, YBX1 knockdown resulted in significantly impaired colony formation with miR-137 mimic or a combination of miR-137 and YBX1-siRNA (Fig. 6B-D and Supplementary Fig. 6 ), confirming that YB1 plays a substantial role in the miR-137-mediated regulation of the invasive behaviour of MPM cells.
Discussion
Recent reports have highlighted the important biological consequences of dysregulated miRNAs in MPM. 14, 18, [26] [27] [28] We have shown that miR-137 belongs to this list of aberrantly expressed miRNAs and that its target, YBX1, is important in the malignant characteristics of MPM. The considerable variation of miR-137 expression in cell lines and tumor samples suggests that it plays a complex role in MPM biology. LOH in the chromosomal region 1p21-22 (which includes MIR137HG) has been observed in MPM, although its consequence is largely unreported. 12 Abnormalities of 1p21-22 are linked to reduced patient survival in other tumor types, including multiple myeloma and plasma cell leukemia. 29, 30 In the present study, we have shown that CNV of MIR137HG correlated with mature microRNA expression in cell lines. In contrast, it was not related to expression in our cohort of F/F patient samples, although it should be noted that this series is small (n ¼ 12). Taking this into account, we cannot rule out a role for CNV in the dysregulation of miR-137 in MPM, and further inquiry with a larger series of patient samples must be conducted to validate our findings.
As CNV alone did not conclusively explain the variable expression we observed, we investigated the role of promoter methylation in miR-137 variance in cell lines and patient samples. We have shown that 5-Aza treatment results in reexpression of miR-137 and have quantitatively demonstrated promoter methylation of MIR137HG (particularly in MPM cells with low basal expression), which is consistent with studies in other tumor types. 20 This supports the notion that methylation is a frequent cause of miR-137 silencing in MPM and suggests that a combination of CNV and promoter methylation leads to the dysregulation of miR-137. Contrary to our findings, studies of miR-137 expression in other tumor types report either a consistent upregulation or, more commonly, downregulation of miR-137. 19, 20, 31 Our data show that miR-137 expression in MPM can be split into three groups: high expressers, moderate expressers, and low expressers. Additionally, although high miR-137 expression is commonly associated with favorable prognosis in other cancers, 20, 32 here we have shown that elevated miR-137 was associated with shorter survival in both series of patients with MPM. We did not see an effect of inhibiting miR-137 on target expression or cell growth but, somewhat unexpectedly, a miR-137 mimic demonstrated tumor suppressive activity in MPM cells, as evidenced by its ability to suppress proliferation, colony formation, migration, and invasion. Similar tumor suppressor effects of miR-137 have been observed in other cancers, 19, 20, 32 with the exception of bladder cancer, in which miR-137 acts as an oncogenic miRNA. 31 Interestingly, although miR-137 loss has been implicated in early colorectal carcinogenesis, 19 another study found that elevated miR-137 was linked to shorter survival in patients with CRC. 33 This group also found that elevating miR-137 induced growth inhibition of CRC cell lines, 33 mirroring our results in MPM cells. It is possible that, similarly to what occurs in CRC, miR-137 loss is linked to MPM tumorigenesis and it plays a tumor suppressor role in early MPM. Then, as the tumor progresses and the biology of the cells change, elevated miR-137 results in increased aggressiveness, explaining its association with poor MPM prognosis. A similar counterintuitive relationship also exists for BAP1, a frequently mutated tumor suppressor in MPM. Germline 3p21 loss is associated with BAP1 cancer syndrome-an increased risk for development of certain cancer types such as mesothelioma. 8 Fascinatingly, although these individuals are more susceptible to MPM development, BAP1 loss significantly increases the median survival of patients with both familial and sporadic MPM after diagnosis. 34 In this study, transfection of miR-137 mimic downregulated CDK6, AKT-2, and YBX1 mRNA levels, and miR-137 directly inhibited the expression of YBX1 expression. MiR-137-mediated CDK6 suppression is linked to growth inhibition and G0/G1 cell cycle arrest, 20 whereas targeting AKT-2 in gastric cancer is linked to dampened tumorigenesis. 35 Other potentially interesting targets of miR-137 include cyclooxygenase 2, 36 which is known to be overexpressed in MPM, 37 and myeloid cell leukemia 1, 38 which we have shown to be oncogenic in MPM. 27 There was a significant negative correlation between YBX1 protein and miR-137 expression, implying a biologically relevant role for this interaction in MPM. When transfected with a combination of miR-137 mimic and YBX1-specific siRNA, most cells responded with reduced growth, whereas all demonstrated significant migration and invasion inhibition to a level similar as with mimic alone. This strongly implies that YBX1 is the most important miR-137 target contributing to migration and invasion in these cells.
YBX1 is an important factor in cancer cell growth, and its overexpression in tumors correlates with poor patient survival. 39 Studies have shown that miR-137-mediated YBX1 downregulation leads to reduced tumorigenic properties of other cancers. 40, 41 YBX1 and its positive regulator twist family bHLH transcription factor 1 are expressed highly in sarcomatoid MPM, and both are linked to epithelial-mesenchymal transition. 42 Here, YBX1 was required for the proliferation of some cell lines and was essential in the colony-forming ability, migration, and invasion of all MPM cells tested, which is consistent with its role in the invasion and migration of other cancer cell types. 39 Taken together, our results show that YBX1 is an important target of miR-137, particularly as it is so integrally involved in invasion and migration of MPM, a malignancy characterized by aggressive local invasion. In addition to miR-137, other factors may contribute to the regulation of YB1 in MPM. Besides miR-137, several miRNAs are known to bind and down-regulate YBX1, such as miR-382. 43 In addition to miRNAs, twist family bHLH transcription factor 1 directly targets and enhances YB1 expression and is differentially expressed in sarcomatoid versus nonsarcomatoid MPM. 42, 44 The application of effective miRNA-and siRNA-based therapies is becoming feasible thanks to the development of novel miRNA delivery methods, such as EnGeneIC Dream Vector nanocells (EDVs). 45 We have performed several preclinical studies utilizing EDVs in MPM 26, 27 and have completed a phase I clinical trial with intravenously administered miRNA-loaded EDVs. 18 Our functional data suggest that YB1 knockdown may have therapeutic significance. Interestingly, nude mice inoculated with NSCLC A549 cells transfected with YBX1 siRNA showed impaired tumor growth compared with siRNA control-transfected cells. 46 Additionally, the ability of EDVs to deliver siRNAs 47 as well as miRNA mimics makes a strong case for use of YBX1-specific siRNAs in future in vivo MPM studies. Additional methods of YBX1 inhibition include use of a cell-permeable peptide able to inhibit YBX1 Serine 102 phosphorylation through molecular docking, which reduced YBX1-mediated growth inhibition and resistance to trastuzumab. 48 This may also be applicable in MPM and warrants further investigation.
In conclusion, our results indicate that miR-137 is dysregulated in MPM because of CNV and hypermethylation of the MIR137HG promoter. Furthermore, elevating miR-137 levels in cells inhibits the malignant characteristics of MPM. This activity is explained, at least in part, by targeting YBX1-an important factor in the colony formation, migration, and invasion of MPM cells. By characterizing an important biological interaction between two regulatory factors involved in the inherent invasiveness of MPM, our study furthers the understanding of MPM biology and provides potential targets for therapeutic intervention.
